Perimeter Medical Crosses the Commercial Threshold: AI-Enabled B-Series Enters the Field
After FDA PMA approval, the company converts its S-Series base and targets a revenue inflection in 2027.
PINK.V · Earnings Call · 2026-08-20
From Seeding to Scaling
When Perimeter Medical reported Q2 2026, the narrative had decisively shifted from seeding the market to crossing a commercial threshold. The company had spent years placing its legacy S-Series OCT systems to build adopters, but the FDA's PMA approval of its next-generation B-Series device in April turned that groundwork into a monetizable opportunity. In the quarter, the company recorded “already made 2 B-Series placements, and the first hospital has commercially deployed the technology” — Adrian Mendes, Likely CEO or Senior Executive · 2026-08-20. That may not sound dramatic, but it is the first revenue-generating step for a product that is expected to command a higher ASP per procedure due to its AI-enabled B Series device. Management's confidence rests on a pipeline that includes both existing S-Series customers looking to upgrade and brand new users exploring OCT in the operating room.The AI Review Hurdle
The real friction in this quarter was not FDA regulatory approval but the internal AI review committees at hospitals—a new gate that was not required for the S-Series. As Adrian Mendes explained, hospitals are still developing these processes, and the company must educate them that “it is not a continuous learning system. it is a fixed AI algorithm” — Adrian Mendes, Likely CEO or Senior Executive · 2026-08-20, so it does not raise the generative-model red flags that have slowed AI adoption elsewhere. This detail is crucial: it positions Perimeter's AI review journey as an education and persistence problem rather than a technical-risk one. The company is deliberately targeting hubs like Dallas, Utah, and Colorado, where it already has a concentration of customers, to shorten sales cycles and leverage word-of-mouth.Financial Discipline and Runway
Amid the launch, Perimeter has kept a tight leash on spending. Revenue reached $503k, up 31% sequentially, entirely from recurring streams—consumables, leases, and service contracts. Operating expenses fell 28% year-over-year and net loss improved 33%, with cash burn down 23% in the first half. CFO Sara Brien confirmed the plan is to “focusing our energies and cost growth in the sales and marketing area” — Sara Brien, Likely CFO or Senior Executive · 2026-08-20 while keeping the balance sheet healthy. The capital raise in Q2 was structured to provide 12 months of cash, and management still projects that runway. This discipline is a deliberate contrast to the prior period, when the limiting factor was the size of the commercial team—a point Adrian made last year: “the thing that's limiting us right now, quite frankly, is the size of our commercial team” — Adrian Mendes, Chief Executive Officer · 2025-08-26. Now that the B-Series is approved, hiring is finally being matched to the opportunity; the company intends to deploy the proceeds from its capital raise into expanding the sales team.Looking Ahead
The company is guiding to materially higher revenue in 2027, built on the conversion of its existing customer base to the B-Series and the onboarding of new accounts. It has also filed with CMS for HCPCS codes, a step toward reimbursement clarity. A potential NASDAQ dual listing is in the planning stages, which could broaden access to capital. The strategic shift from pre-commercial R&D to commercialization is exactly what investors had been waiting for. As Adrian said in closing:. While the numbers are still tiny, the inflection point appears real—the company has a product that is differentiated, a channel that is ready, and a financial plan to get there.we believe that we are approaching a period of rapid revenue growth as B-Series adoption really starts to ramp across the country